Clinical trials Chronic Lymphocytic Leukaemia (CLL)

This is a promotional website intended for healthcare professionals in the UK and Ireland only.

overview

The efficacy and safety of BRUKINSA®▼ in patients with CLL was investigated in two phase 3 randomised studies, SEQUOIA and ALPINE.1–4 Additionally, long-term data have been generated from extended follow-up of the phase 3 ALPINE study.4

SEQUOIA

SEQUOIA (BGB-3111-304) was an international, phase 3, open-label, randomised study of BRUKINSA compared with bendamustine + rituximab (BR) in patients with previously untreated CLL.1,2

ALPINE

ALPINE (BGB-3111-305) was a randomised, multicentre, open-label, phase 3, active controlled study of BRUKINSA compared with ibrutinib in patients with relapsed/refractory (R/R) CLL, with over 3 years of follow up.1,3,4

Study 215

Study 215 was a phase 2, multicentre, open-label, single-arm trial of BRUKINSA in patients with previously treated B-cell lymphoma who have shown intolerance to prior BTK inhibitor treatment.5,6

Learn more about SEQUOIA
Find out more
Learn more about ALPINE
Find out more
Learn more about Study 215
Find out more

Abbreviations: CLL, chronic lymphocytic leukaemia.

References

1. BRUKINSA Summary of Product Characteristics. 2024.

2. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5.

3. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319-32. doi: 10.1056/NEJMoa2211582.

4. Brown JR, et al. ASH annual meeting, December 9–12, 2023. Oral presentation 202.

5. Shadman M, et al. ICML, June 13–17, 2023. Poster 345.

6. Shadman M, et al. Lancet Haematol. 2023;10(1):e35–e45.

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at https://yellowcard.mhra.gov.uk/.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA at www.HPRA.ie.

All adverse events (UK and Ireland) should also be reported to BeiGene at adverse_events@beigene.com; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: medicalinformationEU@beigene.com

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

February 2024 [0823-BRU-PRC-162_v2]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not

You are about to leave the BRUKINSA®▼ site